Corrigendum to “Targeting V-ATPase Isoform Restores Cisplatin Activity in Resistant Ovarian Cancer: Inhibition of Autophagy, Endosome Function, and ERK/MEK Pathway”

Corrigendum to “Targeting V-ATPase Isoform Restores Cisplatin Activity in Resistant Ovarian Cancer: Inhibition of Autophagy, Endosome Function, and ERK/MEK Pathway”

Bibliographic Details
Main Authors:	Arpita Kulshrestha, Gajendra K. Katara, Safaa A. Ibrahim, Valerie Riehl, Manoranjan Sahoo, James Dolan, Kyle W. Meinke, Michael R. Pins, Kenneth D. Beaman
Format:	Article
Language:	English
Published:	Hindawi Limited 2021-01-01
Series:	Journal of Oncology
Online Access:	http://dx.doi.org/10.1155/2021/7563239

Similar Items

Targeting V-ATPase Isoform Restores Cisplatin Activity in Resistant Ovarian Cancer: Inhibition of Autophagy, Endosome Function, and ERK/MEK Pathway
by: Arpita Kulshrestha, et al.
Published: (2019-01-01)

Cancer‐associated V‐ATPase induces delayed apoptosis of protumorigenic neutrophils
by: Safaa A. Ibrahim, et al.
Published: (2020-03-01)

The curious case of vacuolar ATPase: regulation of signaling pathways
by: Sahithi Pamarthy, et al.
Published: (2018-02-01)

Mammary epithelium‐specific inactivation of V‐ATPase reduces stiffness of extracellular matrix and enhances metastasis of breast cancer
by: Gajendra K. Katara, et al.
Published: (2018-02-01)

Interleukin‐22 promotes development of malignant lesions in a mouse model of spontaneous breast cancer
by: Gajendra K. Katara, et al.
Published: (2020-01-01)

In vivo anti‐V‐ATPase antibody treatment delays ovarian tumor growth by increasing antitumor immune responses
by: Arpita Kulshrestha, et al.
Published: (2020-10-01)

Identification of Novel Bisbenzimidazole Derivatives as Anticancer Vacuolar (H+)-ATPase Inhibitors
by: Renukadevi Patil, et al.
Published: (2017-09-01)

Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition
by: Li Yang, et al.
Published: (2017-08-01)

Transcriptional Activation of Gstp1 by MEK/ERK Signaling Confers Chemo-Resistance to Cisplatin in Lung Cancer Stem Cells
by: Jingyuan Li, et al.
Published: (2019-06-01)

Activation of PI3K, Akt, and ERK during early rotavirus infection leads to V-ATPase-dependent endosomal acidification required for uncoating.
by: Mahmoud Soliman, et al.
Published: (2018-01-01)

The MEK5/ERK5 Pathway in Health and Disease
by: Rupesh Paudel, et al.
Published: (2021-07-01)

The MEK/ERK Module Is Reprogrammed in Remodeling Adult Cardiomyocytes
by: Kubin Thomas, et al.
Published: (2020-09-01)

Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway
by: Pui-Kei Wu, et al.
Published: (2020-07-01)

PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways
by: Xueqiong Fu, et al.
Published: (2014-03-01)

MEK inhibitor U0126 reverses protection of axons from Wallerian degeneration independently of MEK-ERK signaling.
by: Catherine Evans, et al.
Published: (2013-01-01)

The Effects of a Novel MEK Inhibitor PD184161 on MEK-ERK Signaling and Growth in Human Liver Cancer
by: Patrick J. Klein, et al.
Published: (2006-01-01)

RNA sequencing analysis to demonstrate Erk dependent and independent functions of Mek
by: Chang Liu, et al.
Published: (2016-03-01)

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
by: Ufuk Degirmenci, et al.
Published: (2020-01-01)

Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer
by: Patricio Gonzalez-Hormazabal, et al.
Published: (2018-12-01)

The MEK/ERK pathway promotes NOTCH signalling in pancreatic cancer cells.
by: Isabelle Tremblay, et al.
Published: (2013-01-01)

The role of the MEK5/ERK5 pathway in human prostate cancer
by: Jenkins, Benjamin L. D.
Published: (2005)

Dabrafenib Promotes Schwann Cell Differentiation by Inhibition of the MEK-ERK Pathway
by: Kyuhee Park, et al.
Published: (2021-04-01)

Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors
by: Saba-El-Leil Marc K, et al.
Published: (2008-11-01)

RASSF9 promotes NSCLC cell proliferation by activating the MEK/ERK axis
by: Jun Yuan, et al.
Published: (2021-07-01)

Rigosertib inhibits MEK1–ERK pathway and alleviates lipopolysaccharide‐induced sepsis
by: Yin Wang, et al.
Published: (2021-09-01)

The Extract of Rhodobacter sphaeroides Inhibits Melanogenesis through the MEK/ERK Signaling Pathway
by: Chen-Hsun Liu, et al.
Published: (2013-06-01)

Robustness of MEK-ERK Dynamics and Origins of Cell-to-Cell Variability in MAPK Signaling
by: Sarah Filippi, et al.
Published: (2016-06-01)

MEK/ERK pathway-mediated GCIP expression involved in metastases of lung adenocarcinoma.
by: Kuan-Ting Lin, et al.

Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition
by: Antonella Catalano, et al.
Published: (2021-04-01)

Bedeutung des MEK5/ERK5-Signalwegs in der zielgerichteten Melanomtherapie
by: Weiß, Neele
Published: (2021)

Regulation of cardiac remodeling by cardiac Na/K-ATPase isoforms
by: Lijun Catherine Liu, et al.
Published: (2016-09-01)

The Structure and Function of the Na,K-ATPase Isoforms in Health and Disease
by: Michael V. Clausen, et al.
Published: (2017-06-01)

Role of Different Isoforms of Na/K-ATPase in Signal Transduction
by: Madan, Namrata
Published: (2014)

Validation of the MEK5 and ERK5 pathway as targets for therapy in prostate cancer and analysis of the ERK5 signalling complex
by: Ramsay, Alison Kay
Published: (2010)

The D Domain of LRRC4 anchors ERK1/2 in the cytoplasm and competitively inhibits MEK/ERK activation in glioma cells
by: Zeyou Wang, et al.
Published: (2016-11-01)

SERPINA11 Inhibits Metastasis in Hepatocellular Carcinoma by Suppressing MEK/ERK Signaling Pathway
by: Song Y, et al.
Published: (2021-07-01)

Detection of activating mutations in RAS/RAF/MEK/ERK and JAK/STAT signaling pathways
by: K. I. Zarubina, et al.
Published: (2020-09-01)

Up-regulation of hepatitis C virus replication and production by inhibition of MEK/ERK signaling.
by: Jean Ndjomou, et al.
Published: (2009-01-01)

BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway
by: Fenfen Wang, et al.
Published: (2018-11-01)

Combination therapies to inhibit the RAF/MEK/ERK pathway in melanoma: we are not done yet.
by: Grant A. McArthur
Published: (2015-07-01)

Cannot write session to /tmp/vufind_sessions/sess_hhses1g6fle4uas3italr76iee